Results 91 to 100 of about 13,497 (214)
Low Weight Loss Response to Incretin Analogs: A Systematic Review
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley +1 more source
Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction
Obesity drives chronic inflammation, insulin resistance, type 2 diabetes, and cancer development through adipocyte dysfunction. Addressing this multisystemic disorder requires integrated strategies beyond diet and exercise, such as thermogenesis activation via menthol or capsinoids and appetite control through GLP‐1/GIP agonists and neuromodulation to ...
Jesica Martínez‐Godfrey +7 more
wiley +1 more source
A novel therapeutic target for diabetes mellitus is incretin-based therapies, glucagon-like peptide-1, and glucose-dependent insulinotropic polypeptides are released from the gastrointestinal (GI) tract and act on beta cells of pancreatic islets by ...
Bhaskar Pal, Moitreyee Chattopadhyay
doaj +1 more source
Improved Glucagon Sensitivity Following Weight Loss: A Systematic Review and Meta‐Analysis
ABSTRACT Objective This systematic review and meta‐analysis investigated the effect of weight loss in people with obesity on two biomarkers of glucagon resistance: fasting plasma glucagon and alanine. Methods A comprehensive search was conducted in Medline and Embase. Random‐effects meta‐analyses and correlation analyses were performed.
Hye‐Rin Charlotte Kim +4 more
wiley +1 more source
In recent years, the popularity of drugs which were firstly introduced as treatment for diabetes type 2 has surged, because of their’s significant effect of managing the body weight especially for patients that suffer for diabetes type 2.
Arkadiusz Staroń +6 more
doaj +1 more source
Lifestyle modification in atrial fibrillation: Mechanisms, phenotypes and ablation outcomes
Abstract Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia and is associated with significant morbidity, mortality and healthcare utilization. Catheter ablation is increasingly used as a rhythm‐control intervention for patients with symptomatic paroxysmal and persistent AF, yet recurrence rates remain suboptimal.
Konstantinos Grigoriou +11 more
wiley +1 more source
The orexigenic system was discovered in 1998. It consists of two neuropeptides, Orexin A and Orexin B. Researchers have focused more on Orexin A, since its intracerebroventricular injection into the lateral ventricle of the rat's brain causes an increase
P. Papakonstantinou +6 more
doaj +1 more source
Abstract Metabolic indices derived from the oral glucose tolerance test (OGTT) and mixed‐meal tolerance test (MMTT) are often interpreted interchangeably; however, these tests represent distinct physiological stimuli. In order to examine potential differential metabolic responses to these tests, we characterized the (dis)agreement between OGTT‐ and ...
Nina Sloth Nielsen +12 more
wiley +1 more source
Reproducibility of Splanchnic Blood Flow Measured Using Phase‐Contrast MRI
Splanchnic vessel blood flow assessment can describe physiology or pathophysiological conditions. Here, we assessed the variation of PC‐MRI‐determined repeated measures of blood flow in four splanchnic vessels in three populations and two MRI‐scanners. We found similar agreements with the means for both scanners and for healthy individuals and patients
Lærke S. Gasbjerg +11 more
wiley +1 more source
A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications
ABSTRACT Objective This review synthesized the components of lifestyle interventions that have been provided in Phase 3 trials of obesity management medications (OMMs). Methods PubMed, CINAHL, and EMBASE were searched for Phase 3 clinical trials published from inception to February 2026 that tested FDA‐approved OMMs.
Ariana M. Chao +5 more
wiley +1 more source

